Medix Biochemica appoints Petra Furu as Chief Executive Officer
14 April 2026, Espoo, Finland – The Board of Directors of Medix Biochemica, a global leader in the supply of mission critical components for the in vitro diagnostics (IVD) industry, appoints Petra Furu as Chief Executive Officer of the company, effective 1 June 2026.
Petra Furu joined Medix Biochemica in June 2025 as Vice President, Immunoassay Business Unit. Prior to joining Medix Biochemica, she held senior leadership roles at Revvity, most recently leading its Reproductive Health business. She holds a PhD in Biochemistry as well as an eMBA and brings nearly 20 years of leadership experience in the IVD industry.
The appointment completes the leadership transition at Medix Biochemica. As part of this transition, Teemu Alahuhta has served as interim CEO since April 2025, when Steve Ferguson stepped down after five-year tenure as CEO.
Over the past 12 months, building on the company’s transformational growth since 2018, Medix Biochemica’s Leadership Team has developed and launched a clear strategy for the next phase of growth. The strategy is centered around four must-win battles which focus on customer centricity, sustainable high-performing solutions, expansion in high-growth markets, and operational excellence.
“Since joining us in June 2025, Petra Furu has already made a significant contribution to Medix Biochemica and demonstrated energetic, people-centered leadership and a strong customer focus throughout. She brings to the CEO role a rare combination of scientific and industry expertise, strategic insight, and the ability to translate strategy into action and business results. The Board is delighted to appoint Petra as CEO and is confident in her ability to lead the company successfully toward its strategic goals,” says Ann-Christine Sundell, the Chair of the Board of Medix Biochemica.
“I am honored by the opportunity to lead Medix Biochemica through the next phase of its transformational journey and drive execution of our four must-win battles to achieve our strategic ambitions. While success will require customer centricity in every decision, focused execution, and close collaboration across the organization, I have great confidence in our people, in the commitment and can-do attitude across Medix Biochemica, and in the path we are on,” says Petra Furu, the incoming CEO of Medix Biochemica.
“I would like to thank the Leadership Team and the entire organization for their drive, commitment, and excellent collaboration throughout the interim CEO period. I am delighted that Petra Furu has been appointed CEO. She is an excellent choice for the role, and her appointment ensures strong continuity in the company’s leadership and the execution of our growth strategy. I wish her every success in the role,” says Teemu Alahuhta, the Vice Chair of the Board of Directors and outgoing interim CEO of Medix Biochemica.
About Medix Biochemica
Medix Biochemica is a market-leading, independent supplier of mission critical components to the in vitro diagnostics (IVD) industry worldwide. The company develops, produces, and supplies high-quality antibodies, antigens, and other critical IVD raw material products to IVD companies worldwide, enabling the delivery of accurate IVD tests to billions of patients. The company's main owner is DevCo Partners, a long-term oriented active owner and development partner dedicated to building world-leading companies in selected niche markets.
.svg){kind=small}
